]>
IRCT20171129037673N1 IRCT 2018-01-29 Kashan University of Medical Sciences The Effect of oxytocin on clinical signs, ACTH & cortisol levels and methamphetamine craving in matrix maintenance treatment The Effect of oxytocin on clinical signs, ACTH & cortisol levels and methamphetamine craving in matrix maintenance treatment 2017-12-22 anticipated 50 Complete https://irct.ir/trial/27898 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment will be done by the use of computer-generated random numbers, Blinding description: Participants, investigators or the assessors of the outcomes are unaware of the study group. Use of Placebo. 2 Drug abuse. Intervention 1: Intervention group: Participants will receive oxytocin nasal spray, 10IU/spray, twice a day until 28 days. (One dose in each nostril (40IU daily)). Intervention 2: Control group: One time 40 IU intranasal saline. Yes - There is a plan to make this available What will be shared: All collected deidentified IPD When: Starting 6 months after publication To whom: For people working in academic institutions and businesses Conditions: The documents will be shared for continuation and being executable of this study Where to obtain: Email address How to obtain: They will be recieved data until two weeks from them email. Comments:
public Abbas Azadbakht
No. 8187695895, East Shahidan
Isfahan Iran (Islamic Republic of) 8187695895 +98 31 3338 1066 azadbakht-a@mail.kaums.ac.ir Kashan University of Medical Sciences scientific Abbas Azadbakht
No. 8187695895, East Shahidan
Isfahan Iran (Islamic Republic of) 8187695895 +98 31 3338 1066 azadbakht-a@mail.kaums.ac.ir Kashan University of Medical Sciences Iran (Islamic Republic of) 18-65 years old Male Methamphetamine dependency as assessed by the substance abuse section of the Structured Clinical Interview of DSM-IV Being at the Matrix Model of treatment. Seeking treatment for methamphetamine use Patients willing to participate in the intervention 18 years 65 years Male Suicide attempts within the past 12 months; suicidal ideas or psychotic symptoms in the past 6 months determined by a study team physician Current opioid, alcohol or sedative physical dependence or cocaine dependence Major cardiovascular disorder Abnormal liver function Having severe psychotic disorders Metabolic diseases such as diabetes Neurological diseases Positive urine tests indicating abuse of any substance or stimulant Unwillingness to participate in the study Z71.5 Drug abuse counseling and surveillance Treatment - Drugs Placebo Intervention group: Participants will receive oxytocin nasal spray, 10IU/spray, twice a day until 28 days. (One dose in each nostril (40IU daily)) Control group: One time 40 IU intranasal saline Measure of desire for methamphetamine. Timepoint: Complete questionnaire weekly. Method of measurement: CCQ-Brief Questionnaire. Depression beck score. Timepoint: Complete questionnaire weekly. Method of measurement: Questionnaire. Anxiety beck score. Timepoint: Complete questionnaire weekly. Method of measurement: Questionnaire. ACTH level in the blood plasma. Timepoint: Before, middle and end of study. Method of measurement: Blood screening. Cortisol level in the blood plasma. Timepoint: Before, middle and end of study. Method of measurement: Blood screening. Kashan University of Medical Sciences Approved 2017-11-17 Ethics committee of kashan univetsity of medical sciences No.8187695895 , East shahidan Ave. isfahan Isfehan Iran (Islamic Republic of)